Under a tenth of patients that would benefit from GLP-1 drugs like Wegovy have access to them, warns the World Health Organization as it releases its first guidance on the medications.
With more than one billion individuals worldwide now obese, it is calling for increased and just access to these injectable treatments.
According to projections, more than two billion will be obese by 2030 if no action is taken.
"Our new guidance acknowledges that obesity is a lifelong illness that can be managed with holistic and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key hurdles to widespread access to the treatments that can help people shift significant weight, explains the body.
GLP-1 Therapy Scarcity
Despite the current most optimistic scenario, the production of these medications would only suffice for about 100 million people – less than 10% of the global need, according to the health organization.
The recommendation encourages countries and companies to expand access, via approaches including licensing agreements.
The intellectual property rights on a key compound – the core ingredient of a leading brand – is scheduled to end in a number of countries in 2026.
How Weight-Loss Jabs Operate
The injections mimick a biological compound to reduce digestion speed, suppress the appetite and increase feelings of fullness so people consume fewer calories.
Patients commonly start to lose weight in the initial weeks of commencing the once-weekly jabs.
Studies indicates users may regain a significant portion a year later of halting the treatment, when their usual hunger resume.
To be carrying excess weight raises your risk for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight concerns individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the WHO.
